I. Breitkreutz

发表

Therapeutics , Targets , and Chemical Biology GF-15 , a Novel Inhibitor of Centrosomal Clustering , Suppresses Tumor Cell Growth In Vitro and In Vivo

H. Goldschmidt, K. Anderson, U. Haberkorn, 2012 .

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

H. Goldschmidt, P. Sonneveld, H. Lokhorst, 2004, Leukemia.

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H. Goldschmidt, P. Sonneveld, E. Vellenga, 2008, Haematologica.

Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure

H. Goldschmidt, A. Ho, M. Zeier, 2014, Bone Marrow Transplantation.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

M. Boccadoro, N. Raje, T. Hideshima, 2007, Blood.

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.

H. Goldschmidt, A. Ho, A. Benner, 2006, Haematologica.

Multiple myeloma

P. Richardson, K. Podar, M. Raab, 2009, The Lancet.

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1

B. Klein, D. Hose, H. Goldschmidt, 2014, Oncotarget.

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

N. Munshi, P. Richardson, D. Chauhan, 2005, Cancer research.

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

K. Anderson, N. Munshi, P. Richardson, 2008, Leukemia.

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

H. Goldschmidt, U. Haberkorn, A. Krämer, 2012, Cancer research.

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

N. Munshi, P. Richardson, D. Chauhan, 2006, Cancer research.

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

G. Tonon, N. Munshi, D. Chauhan, 2008, Blood.

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma

P. Richardson, N. Raje, T. Hideshima, 2008, British journal of haematology.

Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

Stefan Fruehauf, Hartmut Goldschmidt, H. Goldschmidt, 2007, European journal of haematology.

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

H. Goldschmidt, P. Sonneveld, A. Glasmacher, 2003, Annals of Hematology.

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report

S. Gröschel, M. Zeier, C. Müller-Tidow, 2022, EJHaem.

Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity

I. Breitkreutz, K. Anderson, 2008, Expert opinion on drug metabolism & toxicology.

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

N. Munshi, D. McMillin, D. Chauhan, 2006, Blood.

Targeted treatments to improve stem cell outcome: old and new drugs

K. Anderson, M. Raab, I. Breitkreutz, 2007, Bone Marrow Transplantation.

Dose‐intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function

H. Goldschmidt, A. Ho, A. Benner, 2016, Hematological oncology.

Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

H. Goldschmidt, T. Luft, A. Ho, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

H. Goldschmidt, T. Hielscher, C. Müller-Tidow, 2021, Cancers.

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield

H. Goldschmidt, P. Sonneveld, A. Glasmacher, 2007, Leukemia.

Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Leukemia (2008) vol. 22 (1925-1932) 10.1038/leu.2008.174)

K. Anderson, N. Munshi, P. Richardson, 2008 .

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma

N. Munshi, P. Richardson, D. Chauhan, 2007, British journal of haematology.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma

K. Podar, S. Wilhelm, M. Raab, 2018, Annals of Hematology.

(LY317615.HCl) novel, orally available small-molecule inhibitor enzastaurin Targeting PKC in multiple myeloma: in vitro and in vivo effects of the

N. Munshi, D. McMillin, D. Chauhan, 2013 .

Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications.

K. Anderson, Xia Li, N. Munshi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.

Kenneth C Anderson, Iris Breitkreutz, I. Breitkreutz, 2008, Expert opinion on drug metabolism & toxicology.

Recovery of Polyclonal Immunoglobulin Synthesis after Autologous Stem Cell Transplantation in Multiple Myeloma Patients as a Prognostic Factor for Event-Free Survival.

H. Goldschmidt, A. Ho, A. Benner, 2004 .

The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.

H. Goldschmidt, A. Ho, A. Benner, 2006, Haematologica.